Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial.

"Conflicts of Interest: Byung-Kun Kim and Min Kyung Chu, contributing editors of the Journal of Clinical Neurology, were not involved in the editorial evaluation or decision to publish this article.: BKK was a principal investigator for a multicenter trial sponsored by Otsuka Japan, Novartis International AG, Ildong Pharm, Lundbeck, Abbvie and Eli Lilly. BKK worked as an advisory member for Lundbeck Korea and received lecture honoraria from GSK Korea, SK Chemicals, Teva Korea, Abbvie Korea and Yuyu Pharmaceutical Company in the past 24 months. SJC was a site investigator of a multicenter trial sponsored by Allergan, Abbvie Inc., Ildong Pharmaceutical Co., LTD, Novartis International AG, Eli Lilly and Company, Hyundaipharm. Co. Ltd, Biohaven Asia Pacific Ltd, and H. Lundbeck A/S (Lundbeck), and received lecture honoraria from Allergan Korea, WhanIn Pharm Co., LTD, Boryung Pharmaceutical Co.,Ltd., Shinpoong Pharma. Co., Ltd, Yuyu Pharmaceutical Company, and SK chemicals in the past 24 months. JHH is a full-time employee of Eli Lilly and Company. GDA is a full-time employee and a minor stockholder of Eli Lilly and Company. TP is a full-time employee of Eli Lilly and Company.: MK was a site investigator sponsored by Otsuka Korea, Novartis International AG, and Eli Lilly and Company. KO was a site investigator for a multicenter trial sponsored by Otsuka Korea, Novartis International AG, Eli Lilly and Company, Ildong Pharmaceutical, Jeil Pharmaceutical, Korean Drug Co., Samjin Pharmaceutical, and Shin Poong Pharmaceutical. HSM was a principal investigator for a multicenter trial sponsored by Otsuka Korea, Novartis International AG, Ildong Pharm and Eli Lilly and Company. HSM received lecture honoraria from GSK Korea, SK Chemicals, Allergan Korea and Yuyu Pharmaceutical Company in the past 24 months. MKC was a site investigator for a multi-center trial sponsored by Allergan Korea, Biohaven pharmaceuticals, and Lundbeck-Korea. He has received lecture honoraria from Allergan Korea, Handok-Teva, Eli Lilly and Company and Yuyu Pharmaceutical Company in the past 24 months. He received grants from Yonsei University College of Medicine (2018-32-0037) and National Research Foundation of Korea (2019R1F1A1053841)."

"Funding Statement: This study was funded by Eli Lilly and Company."

"The study protocol was reviewed and approved by the appropriate Institutional Review Boards at the different study sites. The clinical trial was conducted according to the Good Clinical Practice and Declaration of Helsinki guidelines. All patients provided written informed consent before participating in the study. The study is registered at ClinicalTrials.gov (NCT02614196)."